ClinicalTrials.gg

Program

LYB005

A development code. Also written as “Low dose antigen of LYB005 without A01B adjuvant”, “Low dose antigen of LYB005 with A01B adjuvant” and “Middle dose antigen of LYB005 without A01B adjuvant”.

Its studies are mostly in Respiratory Syncytial Virus Infections · Infections, led by Guangzhou Patronus Biotech.

Furthest: phase 3, since Oct 26, 20264 company-led studies, 4 open or runningNext primary completion: Sep 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Guangzhou Patronus Biotech44 open or runningphase 3since Oct 26, 2026May 28, 2024Sep 2027phase 3 · NCT07908654

Also a collaborator on its studies: yantai-patronus-biotech-co-ltd.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 28, 2024First study: phase 1 study in Respiratory Syncytial Virus InfectionsFirst studyNCT06442241 · 84 enrolled · Australia
  2. Mar 24, 2025Phase 1 study in Respiratory Syncytial Virus InfectionsNCT06904222 · 90 enrolled · China
  3. Sep 27, 2025Phase 2 study in Respiratory Syncytial Virus InfectionsNCT07208461 · 700 enrolled · China
  4. Oct 26, 2026Phase 3 study in InfectionsPhase 3 reachedNCT07908654 · 25,000 planned · China

Ahead

  1. Sep 2027Primary completion: phase 3 study in InfectionsNCT07908654

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07908654Infections · China3Not yet recruitingSep 202725,000
NCT07208461Respiratory Syncytial Virus Infections · China2Active, not recruitingMar 2026700
NCT06904222Respiratory Syncytial Virus Infections · China1Active, not recruitingAug 202690
NCT06442241Respiratory Syncytial Virus Infections · Australia1Active, not recruitingDec 30, 202584

How it is read

Names in the registry

  • “Low dose antigen of LYB005 without A01B adjuvant”, 2 entries
  • “Low dose antigen of LYB005 with A01B adjuvant”, 2 entries
  • “Middle dose antigen of LYB005 without A01B adjuvant”, 2 entries
  • “Middle dose antigen of LYB005 with A01B adjuvant”, 2 entries
  • “High dose antigen of LYB005 without A01B adjuvant”, 2 entries

Codes read as this program: LYB005.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.